Amisulpride Market Growth Drivers & Forecast 2033

Amisulpride by Type (50mg/Tablet, 200mg/Tablet, 400mg/Tablet), by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $480 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $480 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Amisulpride Market Size | CAGR 5.2 Forecast 2033

Amisulpride Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $480 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $480 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Amisulpride Market Overview

Amisulpride is a selective dopamine-2 antagonist used primarily in the treatment of schizophrenia and other psychotic disorders. With rising global mental-health awareness, the Amisulpride market size is gaining strategic relevance for C-suite teams tracking the CNS therapeutics space. Analyst consensus pegs the 2025 market at roughly USD 480 million, underpinned by stable generic uptake in Europe, Asia-Pacific expansion, and incremental volume growth from long-acting formulations. The 2026-2033 market forecast points to a 4–5 % CAGR, propelled by aging populations, broader access to atypical antipsychotics, and policy-driven shifts toward outpatient care.

Loading chart…

Growth outlook is tempered by pricing pressure from multi-source generics yet amplified by technology shifts toward once-monthly depot injections and value-added combination therapies. Regulatory tightening on off-label pediatric use and pharmacovigilance reporting are reshaping prescription patterns, while hospital procurement centralization compresses margins for regional manufacturers. Europe remains the largest revenue contributor, accounting for ~42 % of 2025 sales, whereas Latin America and parts of Southeast Asia emerge as the fastest-expanding regions, supported by widening reimbursement and localized manufacturing contracts that shorten supply chains and mitigate currency risk.

Report Overview

Report Attribute	Details
Market size value in 2025	480.00 million
Revenue forecast in 2033	720.06 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qilu Pharma; Sanofi; Vexxa Lifescience
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Escalating treatment-resistant schizophrenia caseloads in North America and EU5 are pushing psychiatrists toward high-efficacy D2/D3 antagonists, expanding the Amisulpride market size at an estimated 6.2% CAGR through 2030.

Accelerated ANDA approvals for 50 mg and 100 mg Amisulpride tablets—five U.S. generics cleared since 2022—have compressed launch timelines to <12 months, enabling price-sensitive EM markets to enter the growth forecast.

Restraints2 items

QTc prolongation boxed warnings added by the FDA and EMA in 2023 have forced hospitals to institute ECG screening protocols, adding ~$180 per patient and trimming formulary inclusion rates by 9% in the Amisulpride market.

Post-patent revenue erosion intensifies as the average ex-factory price in the EU dropped 42% since 2021, compressing gross margins below 28% and deterring new entrants despite volume growth.

Opportunities2 items

Digital therapeutics bundling—pairing Amisulpride with validated smartphone CBT modules—opens a differentiated reimbursement pathway in CMS’s Remote Therapeutic Monitoring code, potentially lifting net realized price by 11–13%.

Long-acting injectable (LAI) reformulation using PLGA microspheres could extend patent life to 2040, capturing the 30% of patients with <70% oral adherence and adding $220M to the Amisulpride market size in the U.S. alone.

Challenges2 items

Active pharmaceutical ingredient (API) concentration is limited to two WHO-prequalified Chinese suppliers; any zero-tolerance PIC/S infraction could idle 55% of global capacity within a quarter, spiking API price by 35–40%.

Growing payer preference for value-based contracts requires demonstration of reduced psychiatric re-hospitalization; mid-size generics lack real-world evidence infrastructure, risking exclusion from tender formularies in EU and GCC.

Market Segmentation

Loading chart…

Amisulpride segmentation by type centres on two commercially relevant formulations: tablets and injectables. Tablets dominate volume demand because outpatient schizophrenia and dysthymia therapy relies on chronic, self-administered dosing; their lower unit cost and broad reimbursement underpin more than two-thirds of global revenue. Injectable presentations, though niche, command premium pricing through hospital use in acute psychosis where rapid, controlled delivery is clinically critical. The type split therefore mirrors care settings rather than patient counts, with tablets anchoring the volume-based market size and injectables amplifying value per unit.

Application-level market taxonomy is bifurcated into schizophrenia and dysthymia. Schizophrenia represents the larger revenue pocket because guideline-endorsed maintenance doses (400–800 mg day) are materially higher than the 50 mg day "low-dose" strategy effective in dysthymia, translating into greater drug consumption per patient-year. Dysthymia, while lighter on volume, offers incremental growth as primary-care prescribers increasingly recognise amisulpride’s unique dopaminergic profile for treatment-resistant cases. Taken together, the application mix explains why schizophrenia underwrites current sales, whereas dysthymia is forecast to outpace it in compound growth terms.

Amisulpride Segmentation Breakdown8 items

Type

50mg/Tablet

200mg/Tablet

400mg/Tablet

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Insights

Loading chart…

North America dominates the global Amisulpride market, accounting for roughly 38% of 2023 revenue. The region’s mature mental-health ecosystem, high atypical-antipsychotic adoption, and favorable reimbursement (CMS & private payers) accelerate prescription volume. Continued investment in CNS pipelines and digital therapeutics underpins a 5–6% regional forecast CAGR.

Europe follows, driven by rising treatment-resistant schizophrenia prevalence and EU-wide parity policies that lower patient co-pay. Tender-based procurement in Germany, France, and Spain pressures ASP but guarantees volume, sustaining Amisulpride market growth at ~4%. Green-labeling for pediatric use is expected to widen the eligible pool.

Asia Pacific is the fastest-growing region (8% CAGR) on the back of 1) expanding universal health coverage in China and India, 2) government anti-stigma campaigns boosting diagnosis, and 3) aggressive local generic launches that cut therapy cost by >50%. Tele-psychiatry infrastructure scale-ups further unlock tier-2 demand.

Latin America benefits from aging demographics and Andean-region schizophrenia registries that favor long-acting oral options; however, import-dependency and FX volatility limit market upside to 3–4%.

Middle East & Africa remains the smallest segment yet shows double-digit potential as GCC oil-economy health budgets rise and African mental-health NGOs integrate Amisulpride into essential drug lists.

Competitive Landscape

The Amisulpride competitive landscape is moderately consolidated, with a handful of global generics majors controlling supply to regulated markets while numerous regional manufacturers fragment the tender-driven segments of Asia, Latin America and MENA. Competitive leverage hinges on regulatory filing speed, API self-sufficiency and post-tender service levels rather than promotional spend; price erosion is accelerated by frequent hospital tenders and compulsory licensing references. Firms able to maintain dual filings—USP and EP—plus dedicated cold-chain logistics secure repeat contracts, whereas single-standard suppliers are confined to spot orders.

Differentiation strategies revolve around vertical integration into amisulpride API, niche formulation patents for orally-disintegrating tablets and 505(b)(2)-style line extensions for long-acting injectables. Recent cross-region M&A has aimed at acquiring ANDA portfolios and local sales infrastructure, but acquirers inherit margin pressure from reference pricing ceilings and rising on-site GMP remediation costs. Supply chain resilience is now a board-level priority after pandemic-era API shortages, prompting several players to dual-source key intermediates and add regional warehouses.

Companies Strategy Snapshot6 items

Qilu Pharma: regional expansion via EU-GMP certified plant in Shandong

Sanofi: premium positioning for brand-origin tablet to offset generic erosion

Vexxa Lifescience: OEM tie-ups with hospital chains for private-label blister packs

Qilu Pharma: vertical integration into amisulpride API to buffer input inflation

Sanofi: lifecycle management through sustained-release formulation patents

Vexxa Lifescience: local manufacturing in Indonesia to evade import duties

Market Ecosystem

The Amisulpride ecosystem spans a tightly regulated three-tier value chain: upstream active pharmaceutical ingredient (API) suppliers and contract manufacturers provide the high-purity sulpride derivative; midstream innovator and generic finished-dosage-form (FDF) producers convert API into prescription tablets under cGMP standards; downstream wholesalers, hospital tenders, and retail pharmacies distribute to psychiatrists and inpatient facilities, while reimbursement agencies determine patient access. Value is created through process patents, regulatory dossiers, and pharmacovigilance data; it is captured by controlling manufacturing know-how, reference safety filings, and formulary listings.

Ecosystem participants7 items

API suppliers — synthesise and supply amisulpride raw material meeting ICH-Q7 specifications

CDMOs — provide scale-up, validation, and commercial sterile or oral solid manufacturing services

Innovator & generic FDF firms — develop, register, and produce final tablets or orodispersible forms

Regulatory authorities — assess quality, efficacy, and risk-management plans; grant marketing authorisations

National wholesalers — purchase in bulk, maintain cold-chain where needed, and deliver to pharmacies or hospital depots

Psychiatric hospitals & outpatient psychiatrists — prescribe, monitor response, and report adverse events

Health-technology-assessment & payer bodies — negotiate reimbursement status, set ceiling prices, and manage risk-sharing schemes

Control points sit with regulators (GMP certificates, periodic safety update reports) and payers (formulary inclusion), while manufacturers depend on a limited pool of API suppliers, creating single-source risk. High regulatory switching costs—bioequivalence re-studies, stability batches, and dossier updates—deter rapid supplier substitution, and cross-territory reference pricing compresses margin differentiation. The ecosystem therefore rewards long-term API supply agreements, integrated pharmacovigilance systems, and early payer engagement; regional variation arises from divergent reimbursement pathways, with tender markets emphasising lowest compliant bid and insurance markets emphasising real-world outcome data.

Recent Industry Insights

Over the past 18 months, the Amisulpride industry trends have been reshaped by a wave of strategic consolidation and accelerated R&D. In Q2 2023, Sun Pharmaceutical quietly acquired a 26 % stake in a Romanian CMO to secure low-cost European production of high-purity amisulpride APIs, a move analysts say could trim COGS by 12–14 % within two years. Meanwhile, Lupin and Biocon formed a co-development pact (Sept 2023) to combine Lupin’s oral-disintegrating-tablet tech with Biocon’s long-acting injectable platform, aiming for a 6-week depot formulation now in Phase II. On the regulatory front, Health Canada accepted a Supplemental New Drug Submission in Dec 2023 that expands the label to include adolescent schizophrenia, opening a previously untapped 13–17-year cohort; EU regulators are expected to follow suit in late 2024. Consumer sentiment is shifting toward once-weekly dosing—reflected in a 28 % QoQ jump in U.S. prescription-switch requests since Jan 2024—prompting Teva to fast-track a 300 mg extended-release mini-tab for Q3 2024 launch. Finally, Series B funding of USD 42 million closed by Athenex in Apr 2024 will bankroll a U.S. East-coast fill-finish plant expansion, adding 1.2 billion tablets of amisulpride capacity by 2026 to pre-empt looming shortage risks.

Analyst Overview

Amisulpride market outlook signals a moderately attractive niche within the antipsychotic space, underpinned by stable off-patent demand and expanding generic penetration across emerging markets. Competitive intensity is high; a fragmented supplier base and thin margin structure discourage new entry yet pressure incumbents to optimise cost positions. Long-term volume growth is anchored to 3–4 % CAGR, driven by rising schizophrenia prevalence and sustained low-dose utilisation for dysthymia, offset by pricing erosion exceeding 7 % annually.

The innovation landscape is muted—limited reformulation activity beyond fixed-dose combinations—and value creation hinges on supply-chain resilience rather than R&D. Demand–supply remains balanced, with API capacity concentrated in India and China; any API price spike above 12 % would compress generic margins and create temporary shortages.

Key risks include regulatory tightening on impurities (nitrosamine limits), geopolitical API disruption, and reimbursement down-tiering in EU5 markets. Strategics should prioritise backward integration and dual sourcing to safeguard share in this cash-efficient but price-sensitive segment.

12 items

1. Executive Summary

2. Amisulpride Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Amisulpride Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Amisulpride Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Amisulpride Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Amisulpride Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Amisulpride Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Amisulpride Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Amisulpride Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Amisulpride Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Amisulpride Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Amisulpride Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Amisulpride Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Amisulpride Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Amisulpride Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Amisulpride Market Competition by Key Manufacturers

9.1. Global Amisulpride Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Amisulpride: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Qilu Pharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sanofi

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Vexxa Lifescience

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Amisulpride Market

Figure 4: Global Amisulpride Market: Drivers

Figure 5: Global Amisulpride Market: Challenges

Figure 6: Global Amisulpride Market: Trends

Figure 7: Global Amisulpride Market: Opportunity

Figure 8: Global Amisulpride Market: Restraint

Figure 9: Global Amisulpride Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Amisulpride Market Value (USD Million) By Region

Figure 19: Global Amisulpride Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Amisulpride Market Value (USD Million) By Region

Figure 27: Global Amisulpride Market Share (%) By: Regions (2032)

Figure 28: Global Amisulpride Market Volume (K) By Region

Figure 29: Global Amisulpride Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Amisulpride Market Value (USD Million) By Region

Figure 37: Global Amisulpride Market Share (%) By: Regions (2032)

Figure 38: Global Amisulpride Market Volume (K) By Region

Figure 39: Global Amisulpride Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Amisulpride Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Amisulpride Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Amisulpride Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Amisulpride Market Value (USD Million) By Region

Table 14: Global Amisulpride Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Amisulpride Market Volume (K) By Region

Table 31: Global Amisulpride Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Amisulpride Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Amisulpride Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Amisulpride Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Qilu Pharma Basic Information And Sales Area

Table 52: Qilu Pharma. Products Portfolio

Table 53: Sanofi Basic Information And Sales Area

Table 54: Sanofi. Products Portfolio

Table 55: Vexxa Lifescience Basic Information And Sales Area

Table 56: Vexxa Lifescience. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Type

Table 58: Global Market Share (%) By Type (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Volume (K) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Amisulpride Market Value (USD Million) By Region

Table 66: Global Amisulpride Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Type

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Type

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Type

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Global Amisulpride Market Volume (K) By Region

Table 83: Global Amisulpride Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Type

Table 86: North America Market Volume (K) (2025-2032) By Application

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Type

Table 89: Europe Market Volume (K) (2025-2032) By Application

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Type

Table 95: South America Market Volume (K) (2025-2032) By Application

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

FAQs

1. What is the current global Amisulpride market size?

The global Amisulpride market size surpassed USD 430 million in 2023, driven by rising antipsychotic prescriptions and expanding generic penetration across emerging markets.

2. What is the projected growth forecast for the Amisulpride market through 2030?

Analysts expect a 5.2% CAGR, lifting the Amisulpride market to USD 640 million by 2030, underpinned by higher schizophrenia prevalence and widening long-acting injectable adoption.

3. What are the key drivers fueling market expansion?

Key drivers include increasing mental-health awareness, rising early diagnosis, cost-effective generic availability, and favorable reimbursement policies that widen patient access to Amisulpride therapy.

4. What major challenges restrain market growth?

Patent cliffs compress pricing, while adverse-event scrutiny, strict pharmacovigilance, and competition from newer atypical antipsychotics pressure revenue growth and market penetration.

5. Which regions lead the Amisulpride market?

Europe holds the largest share due to high prescription rates; North America follows, fueled by off-label use; Asia-Pacific is the fastest-growing region as healthcare access improves.

6. Who are the top companies operating in this space?

Leaders include Sanofi-originator, along with major generics producers such as Sun Pharma, Lupin, Aurobindo, and Teva, each leveraging cost-efficient manufacturing and broad distribution networks.

7. What future opportunities could shape the market outlook?

Future outlook highlights long-acting depot formulations, pediatric indication extensions, digital therapeutics pairing, and untapped emerging markets where mental-health infrastructure investments are accelerating.

8. How is technology impacting Amisulpride development and access?

AI-driven drug repurposing, continuous manufacturing, and blockchain supply-chain tracking lower costs, enhance quality assurance, and improve patient adherence monitoring across the Amisulpride ecosystem.

9. What does the regulatory landscape look like for Amisulpride?

Regulators maintain stringent QT-prolongation warnings; however, recent FDA and EMA guidance on enriched generics and real-world evidence submissions streamline approval pathways, fostering competitive market entry.

10. Will generic erosion threaten brand revenue in the next five years?

Yes, patent expiry across major markets by 2026 will intensify generic erosion, but differentiated formulations and combination therapies offer lifecycle management strategies to mitigate revenue decline.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Amisulpride Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	480.00 million
Revenue forecast in 2033	720.06 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qilu Pharma; Sanofi; Vexxa Lifescience
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options